cagrilintide and semaglutide blend (5 mg) + (5 mg) CagriSema Dosage Protocol: Research Reference

P., Iqbal, H

CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide or any of its excipients Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures

The trend toward prolonged pregnancy and reduced neonatal morbidity would require confirmation in larger trials

Use code WELCOME15 for 15% off if youre a first-time customer

The contents of this site contain general information and may not reflect current legal developments or address your situation

Tirzepatide versus retatrutide Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors